Home Clinical Trial Updates

Clinical Trial Updates

Clinical trial updates

ESMO 2020: Durvalumab Demonstrates Sustained Overall Survival in Unresectable Stage III NSCLC

Editorial Team - September 18, 2020

ESMO 2020: Olaparib Improves Median Time Without Disease Progression in BRCAm Ovarian Cancer

ARAMIS Study Show Significantly Longer Overall Survival with Darolutamide in Non-metastatic CRPC

Adjuvant Dabrafenib + Trametinib in Resected Stage III Melanoma w/BRAF Mutations: 5-Year Follow-up

Woman with lung cancer during medical visit

Tepotinib Shows Activity in Advanced NSCLC with a MET Exon 14 Skipping Mutation

Silverback Therapeutics Initiates Phase I clinical study of SBT6050

Editorial Team - September 5, 2020

Study Shows Benefit of Camrelizumab + Cisplatin and Gemcitabine in Nasopharyngeal...

Editorial Team - August 19, 2020

Study Evaluates Diagnostic Value of the Karius Test for Pneumonia in...

Editorial Team - August 3, 2020

$Anti-CD30 CAR-T Cell Therapy Shows Promising Results in Relapsed and Refractory Hodgkin Lymphoma$

Anti-CD30 CAR-T Cell Therapy Shows Promising Results in Relapsed and Refractory...

Editorial Team - July 24, 2020

Accelerated Approval for Kite’s Brexucabtagene Autoleucel in R/R Mantle Cell Lymphoma

Peter Hofland, Ph.D - July 24, 2020

Featured Image: Genmab's Hybridoma and tissue Culture Laboratory. Photo courtesy: 2020 Genmab

Tisotumab Vedotin Shows Positive Results in Phase II Trial in Cervical...

Peter Hofland, Ph.D - June 29, 2020

General view of the 55th Annual Meeting of the American Society of Oncology (ASCO). Courtesey: 2019 ? ASCO/Kristen Norman 2019.

ASCO 2020: Oncoceutics’ ONC201 Demonstrates Clinical Benefit

Peter Hofland, Ph.D - May 30, 2020

Thoughtful young women suffering from ovarian cancer.

FORWARD II Trial of Mirvetuximab Soravtansine + Bevacizumab Demonstrates Encouraging Outcomes

Peter Hofland, Ph.D - May 29, 2020

GlaxoSmithKline (GSK). Photo Courtesy: © 2020 GSK

What to Expect at ASCO 2020: GSK’s Transformational Medicines

Peter Hofland, Ph.D - May 28, 2020

Scientist in biomedical laboratory. Photo courtesy: © 2019 – 2020 Fotolia/Adobe Used with permission.

Interim Results of Phase I Study Confirms Safety with Early Signs...

Danielle Garcia - May 18, 2020

12 3...23 Page 1 of 23

LATEST NEWS

Japan Approves Cetuximab Saratolacan in Unresectable Locally Advanced/Recurrent Head & Neck Cancer

Peter Hofland, Ph.D - September 25, 2020

Astellas Establishes Global Patient-centricity Leadership: Includes Patient Perspective in Research

Peter Hofland, Ph.D - September 23, 2020

Lantern Pharma and Fox Chase Cancer Center Collaborate in Developing LP-184 in Pancreatic Cancer

Editorial Team - September 22, 2020

ESMO 2020: Tisotumab Vedotin Shows Meaningful Clinical Activity in Cervical Cancer

Peter Hofland, Ph.D - September 21, 2020

Black Women Experience Longer Waits and Less Timely Treatment for Breast Cancer

Peter Hofland, Ph.D - September 21, 2020

Press Releases | Cancer

Xstrahl Appoints Dr. Richard Shaffer as Medical Director September 24, 2020
Dr. Shaffer will help support the use of radiation therapy for skin cancer and benign disease(PRWeb September 24, 2020)Read the full story at https://www.prweb.com/releases/xstrahl_appoints_dr_richard_shaffer_as_medical_director/prweb17415571.htm
Uniform Advantage Donates $20,000 to the Breast Cancer Research... September 24, 2020
Uniform Advantage launches a breast cancer awareness campaign and donates $20,000 to the Breast Cancer Research Foundation in support of breast cancer research.(PRWeb September 24, 2020)Read the full story at https://www.prweb.com/releases/uniform_advantage_donates_20_000_to_the_breast_cancer_research_foundation_in_support_of_breast_cancer_research/prweb17419680.htm
The Tisch Cancer Institute Earns Second Consecutive Designation from... September 24, 2020
The Tisch Cancer Institute at Mount Sinai (TCI) has been awarded $13 million as part of the renewal of its National Cancer Institute Cancer Center Designation, a prestigious distinction that is based...(PRWeb September 24, 2020)Read the full story at https://www.prweb.com/releases/the_tisch_cancer_institute_earns_second_consecutive_designation_from_national_cancer_institute/prweb17422135.htm